A novel aptamer-based small RNA delivery platform and its application to cancer therapy

Kaczmarek, 2017, Advances in the delivery of RNA therapeutics: from concept to clinical reality, Genome Med, 9, 60, 10.1186/s13073-017-0450-0 Davidson, 2011, Current prospects for RNA interference-based therapies, Nat Rev Genet, 12, 329, 10.1038/nrg2968 Bobbin, 2016, RNA interference (RNAi)-based therapeutics: delivering on the promise?, Annu Rev Pharmacol Toxicol, 56, 103, 10.1146/annurev-pharmtox-010715-103633 Daka, 2012, RNAi-based nanomedicines for targeted personalized therapy, Adv Drug Deliv Rev, 64, 1508, 10.1016/j.addr.2012.08.014 Dowdy, 2017, Overcoming cellular barriers for RNA therapeutics, Nat Biotechnol, 35, 222, 10.1038/nbt.3802 Johannes, 2018, Current challenges in delivery and cytosolic translocation of therapeutic RNAs, Nucleic Acid Therapeut, 28, 178, 10.1089/nat.2017.0716 Setten, 2019, The current state and future directions of RNAi-based therapeutics, Nat Rev Drug Discov, 18, 421, 10.1038/s41573-019-0017-4 Hu, 2020, Therapeutic siRNA: state of the art, Signal Transduct Targeted Ther, 5, 101, 10.1038/s41392-020-0207-x Saw, 2020, siRNA therapeutics: a clinical reality, Sci China Life Sci, 63, 485, 10.1007/s11427-018-9438-y Juliano, 2016, The delivery of therapeutic oligonucleotides, Nucleic Acids Res, 44, 6518, 10.1093/nar/gkw236 Bouchard, 2010, Discovery and development of therapeutic aptamers, Annu Rev Pharmacol Toxicol, 50, 237, 10.1146/annurev.pharmtox.010909.105547 Zhao, 2015, Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia, Biomaterials, 67, 42, 10.1016/j.biomaterials.2015.07.025 Zhang, 2010, PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Comput Methods Progr Biomed, 99, 306, 10.1016/j.cmpb.2010.01.007 Tanno, 2017, An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth, Blood Adv, 1, 1107, 10.1182/bloodadvances.2017004705 Ercole, 2015, Cholesterol modified self-assemblies and their application to nanomedicine, Biomacromolecules, 16, 1886, 10.1021/acs.biomac.5b00550 Lipfert, 2014, Understanding nucleic acid-ion interactions, Annu Rev Biochem, 83, 813, 10.1146/annurev-biochem-060409-092720 Bissery, 1995, Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience, Anti Cancer Drugs, 6, 339, 10.1097/00001813-199506000-00001 Wang, 2018, Membrane destabilization induced by lipid species increases activity of phosphorothioate-antisense oligonucleotides, Mol Ther Nucleic Acids, 13, 686, 10.1016/j.omtn.2018.10.011 Bhakta, 2009, Magnesium phosphate nanoparticles can be efficiently used in vitro and in vivo as non-viral vectors for targeted gene delivery, J Biomed Nanotechnol, 5, 106, 10.1166/jbn.2009.029 Johnson, 2016, The position of lysosomes within the cell determines their luminal pH, J Cell Biol, 212, 677, 10.1083/jcb.201507112 Wittrup, 2015, Knocking down disease: a progress report on siRNA therapeutics, Nat Rev Genet, 16, 543, 10.1038/nrg3978 Harris, 2003, Effect of pegylation on pharmaceuticals, Nat Rev Drug Discov, 2, 214, 10.1038/nrd1033 Peng, 2015, Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy, Nature, 527, 249, 10.1038/nature15520 Harlin, 2009, Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment, Cancer Res, 69, 3077, 10.1158/0008-5472.CAN-08-2281 Longmire, 2008, Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats, Nanomedicine, 3, 703, 10.2217/17435889.3.5.703 Kore, 2014, Polymeric micelle as multifunctional pharmaceutical carriers, J Nanosci Nanotechnol, 14, 288, 10.1166/jnn.2014.9021 Yin, 2019, Targeting RNA: a transformative therapeutic strategy, Clin Transl Sci, 12, 98, 10.1111/cts.12624 Braasch, 2003, RNA interference in mammalian cells by chemically-modified RNA, Biochemistry, 42, 7967, 10.1021/bi0343774 Crooke, 2017, Cellular uptake and trafficking of antisense oligonucleotides, Nat Biotechnol, 35, 230, 10.1038/nbt.3779 Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat Biotechnol, 35, 238, 10.1038/nbt.3765 Brown, 1994, Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding, J Biol Chem, 269, 26801, 10.1016/S0021-9258(18)47090-1 Sioud, 2007, RNA interference and innate immunity, Adv Drug Deliv Rev, 59, 153, 10.1016/j.addr.2007.03.006 Yee, 1994, Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C, J Biol Chem, 269, 31991, 10.1016/S0021-9258(18)31793-9 Miettinen, 2005, KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem, Mol Morphol, 13, 205 Rajeev, 2015, Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo, Chembiochem, 16, 903, 10.1002/cbic.201500023 Kumar, 2008, T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice, Cell, 134, 577, 10.1016/j.cell.2008.06.034 Cuellar, 2015, Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates, Nucleic Acids Res, 43, 1189, 10.1093/nar/gku1362 Zhou, 2014, Cell-type-specific, aptamer-functionalized agents for targeted disease therapy, Mol Ther Nucleic Acids, 3, e169, 10.1038/mtna.2014.21 Dassie, 2013, Current progress on aptamer-targeted oligonucleotide therapeutics, Ther Deliv, 4, 1527, 10.4155/tde.13.118 Misra, 1998, On the role of magnesium ions in RNA stability, Biopolymers, 48, 113, 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y Owczarzy, 2008, Predicting stability of DNA duplexes in solutions containing magnesium and monovalent cations, Biochemistry, 47, 5336, 10.1021/bi702363u Mariani, 2018, pH-driven RNA strand separation under prebiotically plausible conditions, Biochemistry, 57, 6382, 10.1021/acs.biochem.8b01080 de Rouffignac, 1994, Renal magnesium handling and its hormonal control, Physiol Rev, 74, 305, 10.1152/physrev.1994.74.2.305 Rossi, 2000, The biology of chemokines and their receptors, Annu Rev Immunol, 18, 217, 10.1146/annurev.immunol.18.1.217 Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370 Walser, 2007, Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model, J Immunother, 30, 490, 10.1097/CJI.0b013e318031b551 Chheda, 2016, Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors, J Immunol, 197, 2016, 10.4049/jimmunol.1502376 Sharma, 2011, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat Rev Cancer, 11, 805, 10.1038/nrc3153 Du, 2018, A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy, Cell Res, 28, 416, 10.1038/s41422-018-0011-0 Nagarsheth, 2016, PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer, Cancer Res, 76, 275, 10.1158/0008-5472.CAN-15-1938